Gallstones

Gallstones are solid concretions that form from the components of bile, most often in the gallbladder, a small organ beneath the liver that stores and concentrates bile for release into the small intestine. They are classed by the medical term medical cholelithiasis when they sit in the gallbladder and choledocholithiasis when they lodge in the common bile duct. Most stones are composed mainly of cholesterol, while others are made of calcium bilirubinate and calcium salts. Gallstone disease is one of the most common conditions of the digestive system, and it is a major reason for abdominal surgery worldwide. Its frequency varies by age, sex, ethnicity, and metabolic health, which makes it an important topic in epidemiology and public health.

The entry explains why gallstones form, from the physical chemistry of bile supersaturation and gallbladder stasis to the role of bacterial infection and hemolysis in pigment stones. It then describes how the stones are classified, who is at risk, and how they present, from silent stones found by chance to biliary colic, acute cholecystitis, bile duct obstruction, pancreatitis, and the rare link to gallbladder cancer. Diagnostic methods, the reasoning behind expectant management for asymptomatic stones, and the main treatments are covered next, including cholecystectomy, endoscopic duct clearance, oral dissolution therapy, and shock-wave lithotripsy. The final sections address prevention, special populations, the history of treatment, and open research questions, such as how metabolic drugs and genetic factors affect stone risk.

Definition and anatomical sites

Gallstones, or biliary calculi, are solid concretions formed by the precipitation and aggregation of substances in bile, principally cholesterol and bilirubin-containing compounds. They occur most commonly in the gallbladder, but may also be present in the ducts that carry bile from the liver to the intestine. Cholelithiasis is the general term for gallstone formation or presence, although clinical usage often restricts it to gallbladder stones; cholecystolithiasis specifies that location unambiguously. The presence of stones does not itself imply obstruction or inflammation: many remain within the gallbladder without causing symptoms. (cancer.gov)

The anatomical pathway distinguishes three principal sites. Within the liver, small bile ducts merge into larger intrahepatic ducts, which drain into the right and left hepatic ducts. These unite to form the common hepatic duct; its junction with the cystic duct from the gallbladder forms the common bile duct, which empties into the duodenum, the first part of the small intestine. Choledocholithiasis denotes stones in the common bile duct, whether they formed there or migrated from the gallbladder through the cystic duct. Stones within the intrahepatic ducts are termed hepatolithiasis and may coexist with gallbladder or extrahepatic duct stones. Thus, the site where a stone is detected need not be the site where it originated. (niddk.nih.gov)

The gallbladder is a pear-shaped reservoir beneath the liver, ordinarily holding approximately 30–50 mL of bile. The liver produces bile continuously; between meals, part of this secretion enters the gallbladder, whose lining absorbs water and electrolytes, concentrating the remaining constituents. During digestion, the hormone cholecystokinin stimulates gallbladder contraction and relaxation of the sphincter controlling bile entry into the duodenum. Storage therefore differs from simple passage through a duct: bile remains in a confined cavity, and incomplete emptying gives precipitated crystals more time to aggregate and grow. Concentration is a normal physiological function, whereas prolonged stasis, together with abnormal bile composition, favors stone formation. (ncbi.nlm.nih.gov)

Location determines which flow pathway is interrupted. A stone confined to the gallbladder may remain silent; impaction at its outlet or in the cystic duct can prevent emptying, producing biliary colic and, with persistent obstruction, acute cholecystitis. A common bile duct stone can obstruct drainage from the liver, causing jaundice or bile duct infection. Near the duct’s intestinal outlet, obstruction may also interfere with drainage from the pancreas and precipitate pancreatitis. Intrahepatic stones can obstruct individual duct branches and are associated with recurrent infection and duct narrowing. These are anatomically distinct consequences rather than inevitable stages of a single disease course. (ncbi.nlm.nih.gov)

Stone burden ranges from one large calculus to hundreds of small stones, sometimes with both present; dimensions may vary from sand-grain size to several centimeters. Size and number influence the likelihood of migration and obstruction, so a smaller stone is not necessarily less consequential. A 1997 surgical study found that stones under 5 mm were associated with acute pancreatitis, with an adjusted odds ratio of 4.51 compared with patients presenting with uncomplicated biliary pain. Stone dimensions also affect treatment selection: oral dissolution works best for small cholesterol stones, whereas duct stones require consideration of their location and accessibility for removal. (niddk.nih.gov)

Bile composition and cholesterol solubility

Bile is an aqueous secretion containing cholesterol, phospholipids, bile acids, bilirubin, and electrolytes. Its water-rich environment cannot, by itself, dissolve the quantities of cholesterol carried from the liver. Solubilization depends on bile salts—the ionized forms of bile acids—and phospholipids, principally phosphatidylcholine, also called lecithin. These amphipathic substances have both water-compatible and lipid-compatible regions. They assemble into mixed micelles, whose lipid-compatible interiors accommodate cholesterol. Cholesterol also travels in phospholipid vesicles: small, closed structures with a lipid bilayer surrounding an aqueous compartment. Thus, cholesterol in apparently clear bile is largely carried in molecular aggregates rather than dissolved freely in water; its distribution between micelles and vesicles changes with the concentration and proportions of the biliary lipids. (pmc.ncbi.nlm.nih.gov)

The cholesterol saturation index (CSI), also called the lithogenic index, compares the cholesterol actually present with the maximum amount soluble at equilibrium under the same conditions:

A value below 1 indicates undersaturation, 1 indicates saturation, and above 1 indicates supersaturation; a CSI of 1.5 therefore represents 150% saturation. The denominator is not a fixed concentration. It depends particularly on total lipid concentration and the bile salt-to-phospholipid ratio, as well as bile salt species and other physicochemical conditions. In 1978, Martin C. Carey published experimental tables covering total lipid concentrations of 0.3–30 g/dL, allowing saturation to be calculated from a bile sample’s composition. Excess cholesterol relative to its solubilizing carriers creates a thermodynamic tendency toward precipitation, but the index does not measure how rapidly crystals will appear. (pubmed.ncbi.nlm.nih.gov)

Supersaturated bile can remain metastable: cholesterol stays dispersed temporarily even though a crystalline state is thermodynamically favored. In their 1978 study, Carey and Donald M. Small found supersaturation in approximately half the samples from controls and patients with pigment stones, without observing cholesterol monohydrate crystals in those groups. Supersaturation therefore does not, by itself, establish that cholesterol stones will form. Experimental bile systems show how this temporary stability can fail: cholesterol-rich vesicles emerge, aggregate, and eventually yield crystals. Whether that transition occurs depends on both the degree of supersaturation and the kinetics of crystal nucleation, processes distinct from the subsequent growth of a stone. (jci.org)

The solubilizing bile acid supply is maintained through enterohepatic circulation. After bile enters the intestine, bile acids are reabsorbed—especially through active transport in the terminal ileum—and return through portal blood to the liver for resecretion. Conventional physiological models describe an adult pool of roughly 3 g circulating several times daily, commonly about 6–10 times, with approximately 95% recovery during intestinal passage. Hepatic synthesis replaces fecal losses. Pool size and cycling frequency together influence bile acid delivery: a smaller pool does not necessarily imply a proportionately smaller daily output if recycling accelerates. Nevertheless, loss exceeding replacement can reduce the available pool and alter the balance between cholesterol and its carriers. In a small 1969 tracer study, four patients with ileal resection had a mean fasting pool of 2,212 mg, compared with 2,875 mg in four controls. (journals.physiology.org)

Gallbladder storage changes both concentration and residence time. Water absorption concentrates bile, shifting cholesterol between vesicles and micelles; because equilibrium solubility itself depends on total lipid concentration, concentration cannot be equated simply with increased cholesterol saturation. A paired human study published in 1999 found vesicles in six of seven hepatic bile samples but only two corresponding gallbladder samples, illustrating this redistribution. Meal-associated gallbladder emptying transfers stored bile into the intestine and limits its residence in the reservoir. Reduced or infrequent emptying allows more time for a metastable dispersion to undergo nucleation and retain crystals, even when a single measurement of lipid composition does not capture that kinetic change. (sciencedirect.com)

Types of gallstones by composition

Gallstones are classified principally as cholesterol stones, pigment stones—subdivided into black and brown—and mixed stones. These categories describe the dominant constituents rather than chemically pure substances: cholesterol, calcium bilirubinate, other calcium salts, and organic material can coexist within one stone. “Mixed” is therefore partly classification-dependent; a stone containing cholesterol and pigment may be called a mixed stone or a cholesterol stone with secondary constituents. External color alone is unreliable. A 2018 study using Fourier-transform infrared spectroscopy showed that an otherwise cholesterol-rich stone could appear brown because of a thin surface coating. (pmc.ncbi.nlm.nih.gov)

Cholesterol stones consist predominantly of cholesterol, characteristically in cholesterol monohydrate crystals, with variable amounts of calcium salts, bile pigments, and proteins. Common clinical definitions use a cholesterol content exceeding 50% by weight, although thresholds differ among classification systems. They are typically pale yellow, cream, or yellow-brown, but pigment coatings can produce darker appearances. Stones may be rounded or polyhedral, with smooth or rough surfaces; cut sections often reveal crystals arranged radially around a darker nucleus. Their consistency varies, and cholesterol-rich specimens can be relatively soft. At the microscopic level, plate-like or lamellar crystals form tightly stacked aggregates rather than a homogeneous solid mass. (harrisons.unboundmedicine.com)

Black pigment stones are usually small, irregular, hard, and brittle. Their dark matrix contains polymerized calcium bilirubinate and related bilirubin-derived material, often accompanied by calcium carbonate or calcium phosphate, with relatively little cholesterol. Brown pigment stones contain less-polymerized calcium bilirubinate, variable cholesterol, and calcium salts of fatty acids, especially calcium palmitate and stearate. They are generally brown to yellow-brown, soft, laminated, and sometimes greasy or soap-like. Black stones usually originate in the gallbladder, whereas brown stones characteristically form in stagnant, infected bile ducts. These are chemically and clinically distinct categories: a brown-colored cholesterol stone is not necessarily a brown pigment stone. (elsevier-elibrary.com)

Mixed stones contain substantial proportions of two or more constituents, commonly cholesterol and calcium bilirubinate, sometimes with calcium carbonate or phosphate. They often have conspicuous layers, but color, shape, and hardness depend on the constituent materials. Less common composition-defined types include calcium-carbonate-dominant, calcium-phosphate, calcium-stearate, and protein stones. In Tao Qiao and colleagues’ 2013 analysis of stones from 807 patients, three specimens were classified as protein stones; these were hard, green, and clay- or mud-shaped. Calcium-carbonate-dominant specimens in that series included black coral-like and irregular granular forms with hard or brittle textures. Such unusual appearances require chemical confirmation rather than visual identification alone. (pmc.ncbi.nlm.nih.gov)

Biliary sludge and microlithiasis represent small-particle states that can precede larger stones, but progression is not inevitable. Sludge comprises suspended or sedimented cholesterol monohydrate crystals, calcium bilirubinate granules, and other material within a mucin-rich matrix. It is often asymptomatic and may disappear spontaneously: a 1994 retrospective study found resolution in 40 of 56 patients with newly developed sludge, or 71.4%, while seven subsequently developed stones. Definitions of microlithiasis have varied; a 2023 consensus led by Michal Żorniak and Simon Sirtl distinguished sludge—echogenic material without acoustic shadowing—from discrete calculi measuring no more than 5 mm and producing acoustic shadowing on ultrasonography. (gut.bmj.com)

Composition is established by examining recovered stones using chemical assays, infrared spectroscopy, and sometimes X-ray diffraction, a technique of crystallography. Infrared absorption bands identify constituent compounds; diffraction distinguishes crystalline phases, while electron microscopy and elemental analysis characterize their distribution. Sampling both the core and outer layers matters because composition may vary across a stone, and overlapping absorption bands can complicate interpretation. Type affects treatment response and recurrence: selected noncalcified cholesterol stones can dissolve with ursodeoxycholic acid, whereas pigment and calcified stones do not respond comparably. Brown pigment stones can form again in the ducts after gallbladder removal, unlike stones whose principal site of formation was the removed gallbladder. (pubmed.ncbi.nlm.nih.gov)

Pathogenesis of cholesterol stones

Cholesterol stone formation involves three interacting processes: hepatic secretion of cholesterol beyond bile’s carrying capacity, nucleation of solid crystals, and retention of those crystals in a poorly emptying gallbladder. Increased cholesterol secretion can occur without a corresponding increase in bile acids or phospholipids. The paired transport proteins ABCG5 and ABCG8 promote cholesterol export from hepatocytes into bile; in a 2002 experiment by Liqing Yu and colleagues, mice overexpressing both human genes had more than fivefold higher biliary cholesterol levels, without significant changes in bile acid pool size or composition. This illustrates how altered hepatic transport can selectively increase the cholesterol load presented to the gallbladder. (pubmed.ncbi.nlm.nih.gov)

Supersaturation supplies the thermodynamic drive for crystallization, but does not determine how quickly stones form. Cholesterol-rich lipid particles undergo aggregation and phase changes that ultimately produce solid cholesterol monohydrate crystals. Nucleation is the appearance of the initial stable crystalline particles; subsequent growth adds cholesterol to their surfaces. In an October 1979 study, K. R. Holan and colleagues found that 68% of control bile specimens were cholesterol-supersaturated, demonstrating that supersaturation alone did not distinguish stone-forming bile. Mean crystal nucleation time was nevertheless markedly different: 3 days in 12 samples from patients with cholesterol stones, compared with 15 days in 16 control samples. These were laboratory incubation times, not estimates of the time required to form a gallstone in a person. (pubmed.ncbi.nlm.nih.gov)

The gallbladder’s mucus layer provides both a nucleating environment and a matrix that retains growing crystals. Mucins are large, gel-forming glycoproteins whose secretion increases during experimental stone formation. In a 1981 study by Sum P. Lee, J. Thomas LaMont, and Martin C. Carey, cholesterol-fed prairie dogs showed a fivefold increase in gallbladder glycoprotein production at its peak on day 5; purified human gallbladder mucin gel also promoted cholesterol crystallization from supersaturated bile. Human mucin experiments subsequently showed that its intact polymer structure and lipid-binding regions were important for nucleation. The gel brings lipid particles into contact and supports crystal aggregation and entrapment rather than allowing all particles to leave with emptied bile. Its effect depends on the surrounding lipid environment: a 1984 model-bile experiment found enhanced nucleation at cholesterol saturation indices above 1.0 and at 10%, but not 3%, total lipid by weight. (pubmed.ncbi.nlm.nih.gov)

Gallbladder hypomotility increases the residence time available for these processes. Incomplete emptying leaves a larger residual reservoir in which mucus and crystals can accumulate between meals. Excess cholesterol can also impair contraction, creating a reinforcing relationship between abnormal bile composition and stasis. In experiments reported in 1999, human gallbladder muscle cells from patients with cholesterol stones had increased membrane cholesterol relative to phospholipid, reduced membrane fluidity, and impaired contraction in response to cholecystokinin, a digestive hormone. Incubation with cholesterol-free liposomes for four hours restored membrane properties and contractile responses toward normal, supporting a direct membrane-mediated mechanism rather than attributing poor emptying solely to mechanical obstruction by stones. (pubmed.ncbi.nlm.nih.gov)

Whether retained crystals grow or dissolve depends on cholesterol saturation, bile salt composition, lipid-particle stability, and access of bile to crystal surfaces. Persistent supersaturation favors deposition, while existing cholesterol crystals provide seeds for further precipitation. Bile with greater cholesterol-solubilizing capacity can instead remove cholesterol from crystal surfaces. The identity of the bile salts matters as well as their amount: experiments with ursodeoxycholate-rich bile demonstrated dissolution through both micellar transport and liquid-crystalline intermediates. Hydrophilic bile salts also inhibited precipitation in supersaturated model bile by stabilizing a liquid-crystalline phase. Thus, a fall in cholesterol saturation and stabilization of its lipid carriers can oppose crystal accumulation, whereas prolonged retention in mucin-rich, persistently supersaturated bile favors enlargement and aggregation into stones. (pubmed.ncbi.nlm.nih.gov)

Pathogenesis of pigment stones

Black pigment stones develop principally in the gallbladder when bile becomes supersaturated with calcium salts of unconjugated bilirubin. The liver normally converts bilirubin into more water-soluble glucuronide conjugates before secreting it into bile. Hydrolysis of these conjugates by endogenous β-glucuronidase releases unconjugated bilirubin; its negatively charged forms combine with calcium to produce poorly soluble calcium bilirubinate. Precipitation therefore depends on local bilirubin concentration, available calcium, and the capacity of bile salts to maintain solubility—not simply on the serum bilirubin concentration. Black stones typically form without a requirement for bacterial infection, distinguishing their usual mechanism from that of brown stones. (pmc.ncbi.nlm.nih.gov)

The precipitated pigment accumulates within an organic matrix and undergoes chemical changes, including polymerization, that help produce the characteristic black material. Calcium phosphate and calcium carbonate may also become incorporated. Mucin, a glycoprotein secreted by the gallbladder epithelium, binds pigment and provides a framework for aggregation. In a 1983 study, J. T. LaMont and colleagues found a mean glycoprotein content of 12.4% in eight black pigment stones and isolated high-molecular-weight mucin that remained associated with bile pigment after extensive purification. These findings support a role for the matrix in consolidating calcium bilirubinate precipitates into stones. (pubmed.ncbi.nlm.nih.gov)

Chronic hemolysis increases the bilirubin load by accelerating the destruction of red blood cells and the breakdown of heme from hemoglobin. Increased hepatic secretion of bilirubin conjugates supplies more substrate for deconjugation within bile, favoring calcium bilirubinate supersaturation. This explains the association of black stones with sickle cell disease, thalassemia, and hereditary spherocytosis. Nevertheless, hemolysis does not inevitably produce stones: bilirubin conjugation and other local conditions modify susceptibility. A 2008 study of 324 children with sickle cell anemia found documented gallbladder disease in 39% of children with the UGT1A1 promoter 7/7 genotype, compared with 18.2% with 6/7 and 9.9% with 6/6. The endpoint was gallbladder disease rather than chemically verified pigment stones, but the results demonstrate substantial variation in susceptibility within a hemolytic disorder. (pmc.ncbi.nlm.nih.gov)

Brown pigment stones form mainly within intrahepatic or extrahepatic bile ducts through the interaction of infection and impaired drainage. Biliary stasis associated with duct strictures or obstruction favors bacterial persistence; parasites, including Clonorchis sinensis and Ascaris lumbricoides, can contribute to obstruction and infection. Enteric bacteria produce β-glucuronidase, which hydrolyzes bilirubin glucuronides and increases unconjugated bilirubin available for calcium bilirubinate precipitation. Bacterial phospholipases also hydrolyze biliary phospholipids, releasing fatty acids that precipitate as calcium soaps, notably calcium palmitate. In a 1992 study, L. Vitetta and A. Sali examined primary bile duct stones from five patients: calcium bilirubinate and calcium palmitate were prominent constituents, and every bile culture contained at least one β-glucuronidase-active bacterial species. (pmc.ncbi.nlm.nih.gov)

Bacterial extracellular slime supplies an additional matrix that traps and aggregates precipitates. In 2000, Lygia Stewart and colleagues tested 91 biliary bacterial isolates from 61 patients; 73% produced slime, whereas 38% produced β-glucuronidase, indicating that enzyme-mediated deconjugation is not the only bacterial contribution. Unlike cholesterol-stone formation, pigment-stone formation does not require cholesterol supersaturation: the central insoluble material is bilirubin-derived calcium salt. Supporting this distinction, analysis of two infants with infected bile and brown stones found that their bile was not saturated with cholesterol, despite abundant unconjugated bilirubin and calcium-palmitate-containing stones. (pubmed.ncbi.nlm.nih.gov)

Risk factors

Female sex and increasing age are established risk factors. The hormonal contribution is particularly important for cholesterol stones: estrogen favors cholesterol secretion into bile, while progesterone-related changes reduce gallbladder emptying. During pregnancy, these effects combine increased cholesterol saturation with prolonged retention of bile and crystals. Human physiological studies have documented increased saturation in the second and third trimesters and incomplete gallbladder emptying in later pregnancy. Age also affects bile composition. In a 1985 study of 60 healthy, nonobese, stone-free adults, Kurt Einarsson and colleagues found that cholesterol saturation increased with age; additional measurements linked this change to greater hepatic cholesterol secretion and reduced bile acid synthesis. These mechanisms help explain susceptibility without implying that every older adult or pregnant person develops stones. (niddk.nih.gov)

Exogenous hormones can increase risk, although effects depend on the preparation and exposure. Estrogen-containing contraceptives and menopausal hormone therapy are recognized risk factors. Strong evidence for oral menopausal therapy came from two Women’s Health Initiative randomized trials, reported by Dominic J. Cirillo and colleagues in 2005, involving 22,579 women aged 50–79 without previous gallbladder removal. Conjugated equine estrogens alone increased the hazard of diagnosed cholelithiasis to 1.86 times that with placebo; estrogen plus medroxyprogesterone acetate increased it to 1.68 times. Annual rates of the broader outcome of gallbladder disease or surgery were 78 versus 47 per 10,000 person-years for estrogen alone and 55 versus 35 for combined therapy. These outcomes concern clinically recognized disease, not systematic detection of all newly formed stones. (niddk.nih.gov)

Obesity, especially abdominal adiposity, promotes cholesterol-rich bile and may be accompanied by a larger, poorly emptying gallbladder. Insulin resistance and diabetes mellitus are also associated with gallstones. Mechanistic support comes partly from experimental models: in a 2008 study by Sudha B. Biddinger and colleagues, mice lacking hepatic insulin receptors showed increased expression of the cholesterol transporters Abcg5 and Abcg8, greater biliary cholesterol secretion, and altered bile acid synthesis. This establishes a biological pathway in mice rather than a quantitative estimate of human risk. Dyslipidemia associated with gallstones includes high triglycerides and low HDL cholesterol; susceptibility therefore cannot be reduced to a high blood cholesterol concentration alone. (niddk.nih.gov)

Rapid weight loss creates a different risk from sustained obesity. Mobilization of body fat increases cholesterol delivery into bile, while prolonged fasting and restricted food intake impair gallbladder emptying. Very-low-calorie diets can therefore combine cholesterol supersaturation with stasis. A Swedish matched cohort study published in 2014 compared 3,320 participants consuming 500 kcal daily with 3,320 consuming 1,200–1,500 kcal daily during an initial three-month weight-loss phase. Over one year, gallstones requiring hospital care occurred at rates of 152 versus 44 per 10,000 person-years, respectively, with a hazard ratio of 3.4. Adjustment for early weight loss reduced, but did not eliminate, the association. Repeated weight loss and regain is another recognized risk exposure. (niddk.nih.gov)

Family history reflects both inherited susceptibility and shared exposures. A 2005 Swedish study of 43,141 twin pairs estimated that genetic effects accounted for 25% of variation in susceptibility to symptomatic gallstone disease, shared environmental effects for 13%, and individual-specific environmental effects for 62%; these are population variance estimates, not percentages of an individual’s stones attributable to each cause. A concrete genetic example is the ABCG8 D19H variant: Stephan Buch and colleagues reported in 2007 that carriers had an overall odds ratio of 2.2 in their German sample, rising to 3.3 for cholesterol stones. The association implicates hepatic cholesterol transport. Inherited susceptibility operates alongside obesity, hormonal exposure, and dietary patterns; high-calorie diets rich in refined carbohydrates and low in fiber are recognized associated exposures. (pubmed.ncbi.nlm.nih.gov)

Epidemiology and geographic variation

Gallstones affect approximately 10–20% of adults in Western populations, with prevalence increasing with age and generally higher in women. Comparisons depend on the definition used: population surveys commonly count both stones detected by ultrasonography and previous gallbladder removal, rather than existing stones alone. In the United States, James E. Everhart and colleagues analyzed ultrasound examinations from more than 14,000 participants in the 1988–1994 National Health and Nutrition Examination Survey. Their 1999 report estimated that 6.3 million men and 14.2 million women aged 20–74 had gallstones or a previous cholecystectomy. Age-standardized prevalence among non-Hispanic white participants was 8.6% in men and 16.6% in women; corresponding figures were 8.9% and 26.7% among Mexican Americans and 5.3% and 13.9% among non-Hispanic Black participants. These historical estimates are not measurements of current US prevalence. (journal-of-hepatology.eu)

Particularly high rates have been documented in some Indigenous populations of the Americas. The Strong Heart Study, reported in 2002, found that 64.1% of participating American Indian women had gallbladder disease: 17.8% had stones and 46.3% had undergone cholecystectomy. A separate study published in 2020 examined 258 asymptomatic Aymara adults from two rural communities in northern Chile, recruited during 2014–2018. Ultrasound identified stones in 76 participants, or 29.5%, while another 32, or 12.4%, had previously undergone cholecystectomy, producing a combined prevalence of 41.9%. Because this was a volunteer sample with more women than men, it should not be treated as a prevalence estimate for all Aymara people or Indigenous populations generally. (pubmed.ncbi.nlm.nih.gov)

Geographic variation also concerns stone composition and location. Cholesterol stones predominate in Western gallbladder disease, whereas pigment stones have historically accounted for a larger share of disease in parts of Asia, especially stones formed within bile ducts. The distribution is neither uniform across Asia nor constant over time. A 1964 Japanese investigation analyzed stones from 812 people: 46.6% were cholesterol stones and 41.5% bilirubin stones. Cholesterol stones accounted for 69.5% of the Tokyo specimens, while bilirubin stones accounted for 69.4% in northeastern rural villages. These were proportions among collected stones, not population prevalence figures. (pmc.ncbi.nlm.nih.gov)

Subsequent East Asian studies documented substantial changes in composition. A 1993 Japanese report described an increase in the cholesterol-stone share from 46.7% to 66.9% over approximately 25 years, alongside a decline in calcium bilirubinate stones from 41.5% to 21.0%. Increased dietary fat intake and reduced parasitic infection following improvements in sanitation were proposed as contributors. The trend was not indefinitely upward: Kazuhiko Tsunoda and colleagues’ 2004 analysis of 1,264 cholecystectomy patients treated in Niigata during 1971–1999 found that the cholesterol-stone proportion increased until the 1970s and declined thereafter. Its correlation with national calorie intake was an ecological association, not proof that dietary change caused an individual patient’s stones. (pubmed.ncbi.nlm.nih.gov)

Imaging surveys reveal a large reservoir of clinically silent stones: approximately 80% of stone carriers are asymptomatic. New stone formation must be distinguished from the development of symptoms in someone who already has stones. In the Italian MICOL follow-up study, published in 2008, 424 of 9,517 initially stone-free participants had stones detected and 61 had undergone cholecystectomy, yielding an estimated annual gallstone-disease incidence of 0.67%. For established asymptomatic stones, the 2016 European Association for the Study of the Liver guidelines estimated annual symptom development at approximately 0.7–2.5%, compared with an annual complication rate of 0.1–0.3%. These follow-up rates are not necessarily constant throughout life. (pmc.ncbi.nlm.nih.gov)

Rising obesity and population aging can increase disease burden because higher body mass index and advancing age predict incident stones; the MICOL study identified both associations in men and women. Dietary changes may additionally alter the balance between cholesterol and pigment stones, although their contribution is difficult to separate from changes in infection, sanitation, and metabolic health. Absolute burden and age-standardized rates can move in opposite directions: a Global Burden of Disease analysis estimated that gallbladder and biliary disease cases increased by 67.3% between 1990 and 2021 while age-standardized prevalence declined by 13.3%. That broader disease category is not equivalent to ultrasound-detected gallstones alone. (pmc.ncbi.nlm.nih.gov)

Clinical presentation

Silent gallstones cause no attributable symptoms and are usually discovered incidentally during imaging performed for another reason, often ultrasonography. Approximately 80% of people with gallstones are asymptomatic. The European Association for the Study of the Liver’s 2016 guidelines estimated that about 20% of initially asymptomatic patients develop symptoms within 20 years, implying that approximately four-fifths remain symptom-free over that interval. Stones confined to an otherwise normal gallbladder and biliary tree generally require no treatment solely because they are present. This differs from stones identified in the common bile duct. (journal-of-hepatology.eu)

Biliary colic results when a stone temporarily obstructs the cystic duct: gallbladder contraction against the obstruction increases pressure and distends the organ. Pain usually occurs in the right upper quadrant, beneath the right ribs, or in the epigastrium—the upper central abdomen—and may radiate toward the right shoulder or back. Despite the term “colic,” the pain is typically sustained rather than a succession of brief cramps. An attack generally lasts more than 30 minutes and up to several hours, and can be accompanied by nausea or vomiting. Attacks often follow a heavy meal and occur in the evening or at night, although a meal association is not essential. Pain subsides when the stone shifts and obstruction resolves; subsequent attacks are common after the first episode. (cdn.ncpodcast.net)

Acute cholecystitis is distinguished from uncomplicated biliary colic by persistent pain and evidence of gallbladder inflammation. Typical findings include right upper quadrant tenderness, fever, nausea, and vomiting. A positive Murphy’s sign occurs when pressure beneath the right costal margin during deep inspiration causes pain sufficient to interrupt inspiration. The Tokyo Guidelines 2018, developed by Masamichi Yokoe and colleagues, identify local findings such as Murphy’s sign or right upper quadrant tenderness together with systemic inflammation—fever, an elevated white blood cell count, or increased C-reactive protein—as grounds for suspected acute cholecystitis; characteristic imaging findings establish a definite diagnosis. No single symptom or examination finding establishes the diagnosis on its own. (onlinelibrary.wiley.com)

Pain persisting for several hours, particularly when accompanied by fever or chills, is a warning presentation requiring urgent assessment rather than classification as an uncomplicated, self-limited attack. Jaundice, dark urine, or pale stools suggest impaired bile drainage and possible disease beyond the gallbladder. These findings can accompany obstruction, infection, or pancreatic inflammation; the associated complications are considered separately. (niddk.nih.gov)

The differential diagnosis includes peptic ulcer disease, gastroesophageal reflux, acute pancreatitis, hepatitis, and cardiac ischemia, including myocardial infarction. Gallstones detected on imaging do not necessarily explain concurrent abdominal pain. Heartburn, bloating, and other dyspeptic symptoms are insufficiently specific to attribute to stones. Distinguishing biliary pain from these alternatives depends on the pain pattern, associated manifestations, examination, laboratory findings, and appropriate imaging rather than the incidental presence of gallstones alone. (cdn.ncpodcast.net)

Complications and bile duct disease

Choledocholithiasis, the presence of stones in the common bile duct, can obstruct bile drainage and cause pancreatitis or infection of the biliary tree. Common bile duct stones are found in approximately 5–10% of patients undergoing laparoscopic gallbladder removal for symptomatic gallstones. Obstruction may be intermittent as a stone moves, or persistent when it becomes impacted; impaired drainage can produce jaundice and dilation of the upstream ducts. Obstruction and infection are distinct processes: an obstructing stone does not necessarily cause cholangitis, but it creates conditions in which infection can become life-threatening. (asge.org)

Acute cholangitis develops when bacterial infection occurs in an obstructed biliary system. Rising duct pressure facilitates the passage of bacteria and their products into the circulation, potentially causing sepsis and organ dysfunction. Charcot’s triad—named after Jean-Martin Charcot—consists of fever, right upper quadrant or upper abdominal pain, and jaundice. Although strongly suggestive of cholangitis, the complete triad is frequently absent: the Tokyo Guidelines 2018 cited multicenter series in which it occurred in only 21.2–26.4% of cases. Its absence therefore does not exclude infection. Hypotension and altered consciousness added to the triad constitute Reynolds’ pentad, indicating severe systemic involvement. Clinical assessment combines inflammatory findings, evidence of impaired bile flow, and imaging evidence of obstruction; severe cholangitis requires urgent biliary drainage as well as antimicrobial treatment. (pmc.ncbi.nlm.nih.gov)

Gallstone pancreatitis occurs when a migrating stone obstructs the pancreatic outflow near the ampulla of Vater, where the bile and pancreatic ducts normally empty into the duodenum. Even transient obstruction can initiate pancreatic injury, so inflammation may continue after the stone has passed. Premature activation of digestive enzymes within the pancreas contributes to tissue damage. The resulting illness ranges from self-limited inflammation to pancreatic necrosis and respiratory, cardiovascular, or renal failure. Under the revised Atlanta classification, developed in 2012, severe acute pancreatitis is defined by organ failure persisting for more than 48 hours; necrosis without persistent organ failure does not by itself establish this severity category. (niddk.nih.gov)

Persistent gallbladder inflammation can produce empyema, an accumulation of pus, or gangrene, in which ischemic tissue becomes necrotic. Perforation may release bile and infected material into the peritoneal cavity, causing generalized peritonitis, or remain localized as a collection beside the gallbladder. Chronic perforation into an adjacent bowel segment can create a biliary–enteric fistula. A large stone entering the intestine through such a connection may cause gallstone ileus, a mechanical obstruction despite its name. The usual connection is between the gallbladder and duodenum, and impaction commonly occurs in the terminal ileum. In a 1990 surgical series of 37 patients, whose median age was 78 years, 27 obstructions—73%—were located in the terminal ileum. (ncbi.nlm.nih.gov)

Gallstones are also associated with gallbladder carcinoma, although most people with stones never develop this cancer. Up to four-fifths of patients with gallbladder cancer have stones at diagnosis; this co-occurrence is not equivalent to the proportion of cancers proven to have been caused by stones. Chronic inflammation is a proposed link. Stone size matters epidemiologically: A. K. Diehl’s 1983 case–control study of 81 cancer cases reported an odds ratio of 10.1 for stones at least 3 cm across compared with stones smaller than 1 cm, while explicitly noting the need for replication. Porcelain gallbladder denotes calcification of the gallbladder wall, with risk differing by calcification pattern. A 2001 study by A. E. Stephen and D. L. Berger found cancer in approximately 7% of 27 gallbladders with selective mucosal calcification, but in none of 17 with complete intramural calcification; these small retrospective groups do not establish a universal risk percentage. (cancer.org)

Diagnosis

Abdominal ultrasonography is the first-line imaging test for suspected gallbladder stones. Reported sensitivity is approximately 95–97% in conventional examinations, although performance varies with the population and examination conditions. Stones typically appear as bright echogenic structures with posterior acoustic shadows; movement when the patient changes position helps distinguish them from fixed gallbladder polyps. Ultrasound also evaluates gallbladder distension, wall thickening, surrounding fluid, and bile-duct dilatation. Very small stones and sludge may be overlooked, and severe obesity can impair visualization. Sensitivity is substantially lower for common bile duct stones than for gallbladder stones, so a negative examination does not exclude choledocholithiasis when clinical or biochemical evidence suggests obstruction. (acsearch.acr.org)

Computed tomography (CT) is less sensitive for stones themselves because detection depends on their attenuation relative to bile: calcified stones are conspicuous, whereas some noncalcified stones are difficult to distinguish. Its principal diagnostic value is evaluating alternative causes of abdominal pain and complications such as perforation, gas within the gallbladder wall, or abscess formation. Magnetic resonance cholangiopancreatography (MRCP), a specialized application of magnetic resonance imaging, depicts the biliary ducts noninvasively and is particularly useful for locating duct stones and strictures. Endoscopic ultrasonography (EUS) provides high-resolution imaging from the stomach and duodenum and can identify small stones missed by other examinations. The 2019 American Society for Gastrointestinal Endoscopy guideline reported pooled sensitivities of 97% for EUS and 87% for MRCP, with respective specificities of 90% and 92%, in five prospective comparative studies involving 272 patients. Either test is used to clarify intermediate-probability duct disease; purely diagnostic endoscopic retrograde cholangiopancreatography is generally avoided because of its procedural risks. (acsearch.acr.org)

Laboratory testing primarily identifies complications rather than gallbladder stones. Bilirubin, alkaline phosphatase, gamma-glutamyl transferase, and aminotransferases help assess biliary obstruction: increased bilirubin and cholestatic enzymes support impaired bile drainage, but do not establish that a stone is the cause. White-cell count and C-reactive protein indicate systemic inflammation and contribute to the assessment of cholecystitis or cholangitis. Serum lipase is measured when pancreatic inflammation is suspected. In uncomplicated biliary colic, laboratory results are usually normal; therefore, normal blood tests do not exclude symptomatic gallbladder stones. The distinction rests on the combined clinical, biochemical, and imaging findings rather than any single result. (onlinelibrary.wiley.com)

For acute cholecystitis, the Tokyo Guidelines 2018 require at least one local inflammatory sign—Murphy’s sign or right-upper-quadrant pain, tenderness, or a mass—and at least one systemic sign, such as fever, elevated C-reactive protein, or an increased white-cell count, for a suspected diagnosis. Characteristic imaging findings are additionally required for a definite diagnosis. These include gallbladder wall thickening, distension, pericholecystic fluid, and a sonographic Murphy’s sign: focal pain elicited by pressure from the ultrasound probe directly over the gallbladder. Stones alone do not establish acute cholecystitis. When the ultrasound findings are inconclusive, hepatobiliary scintigraphy can demonstrate cystic-duct obstruction through failure of the gallbladder to fill with tracer. (onlinelibrary.wiley.com)

Acute cholangitis is distinguished by evidence of systemic inflammation, cholestasis, and biliary obstruction or its cause on imaging. Under the Tokyo Guidelines 2018, one finding from each of these three categories establishes a definite diagnosis; inflammation plus either cholestasis or an imaging finding establishes a suspected diagnosis. The complete combination of fever, jaundice, and right-upper-quadrant pain is not required. Acute pancreatitis, by contrast, requires at least two of three findings: characteristic persistent upper-abdominal pain, serum lipase or amylase at least three times the upper limit of normal, and characteristic imaging abnormalities. If pain and enzyme criteria are met, pancreatic imaging is not necessary merely to confirm the diagnosis. Gallstones or duct stones identified during the investigation support a biliary cause, but pancreatitis and persistent bile-duct obstruction remain separate diagnostic questions. (onlinelibrary.wiley.com)

Management of asymptomatic and mildly symptomatic stones

Expectant management—leaving stones untreated unless clinically relevant symptoms develop—is the usual approach to incidental gallbladder stones in an otherwise normal gallbladder and biliary tree. The 2016 European Association for the Study of the Liver (EASL) guideline estimates that 0.7–2.5% of people with asymptomatic stones develop symptoms annually, while complications occur in approximately 0.1–0.3% annually. These population averages inform the balance between observation and preventive intervention; they do not reliably predict an individual’s course. Routine cholecystectomy would expose many people who would remain symptom-free to operative harms. NICE’s 2014 guideline therefore recommends no treatment for uncomplicated asymptomatic gallbladder stones unless symptoms appear. This policy does not extend to stones in the common bile duct. (journal-of-hepatology.eu)

Preventive gallbladder removal may nevertheless be considered when imaging identifies features associated with increased concern for gallbladder cancer. The Japanese 2021 clinical practice guideline lists stones larger than 3 cm, porcelain gallbladder, marked wall thickening, and a stone-filled gallbladder among higher-risk findings; its recommendation to consider surgery in such cases is weak because supporting evidence is limited. Porcelain gallbladder denotes calcification of the gallbladder wall, but it is not a uniform indication: EASL distinguishes homogeneous wall calcification, for which surgery may be avoided, from patchy calcification associated with greater malignancy concern. Coexisting polyps require a separate assessment. The joint European polyp guideline published in 2022 recommends cholecystectomy for lesions measuring at least 10 mm in patients fit for surgery, and for 6–9 mm lesions accompanied by risk factors such as age over 60 years, primary sclerosing cholangitis, or sessile morphology. These indications concern possible neoplasia rather than stone symptoms alone. (pmc.ncbi.nlm.nih.gov)

For uncomplicated biliary colic, conservative treatment principally provides symptom relief rather than removal of the obstructing stone. Nonsteroidal anti-inflammatory drugs, such as diclofenac, are effective analgesics and generally control pain better than antispasmodics; renal impairment, gastrointestinal complications, and previous hypersensitivity limit their use. Acetaminophen may suffice for less severe episodes, while opioids are sometimes used for severe pain. Supportive management includes identifying food or drink that reproducibly triggers attacks and providing a plan for reassessment if symptoms recur or worsen. Elective laparoscopic surgery remains the guideline-standard definitive option for symptomatic gallbladder stones, but observation with access to later surgery is an alternative for selected uncomplicated cases. (journal-of-hepatology.eu)

The 2023 C-GALL randomized controlled trial, led by Irfan Ahmed and colleagues, compared conservative management with a surgical strategy in 434 adults at 20 UK centres. At 18 months, 25% of participants allocated to conservative management and 67% allocated to surgery had undergone cholecystectomy. Overall bodily-pain scores did not differ significantly between groups, although gallbladder-specific quality-of-life measures favoured the surgical group. By 24 months, 29% of the conservative group had undergone surgery. These results support observation as a short-term option rather than establish that surgery is unnecessary: substantial crossover occurred, follow-up was limited, and patients with bile duct stones, previous pancreatitis, obstructive jaundice, or suspected gallbladder cancer were excluded. (bmj.com)

Diabetes mellitus alone does not justify prophylactic treatment of asymptomatic stones. In older adults and people with multiple comorbidities, the operative assessment also weighs functional dependence and cardiopulmonary disease against symptom burden and the possibility of later intervention. A 2023 analysis of laparoscopic cholecystectomy patients aged 65 years or older used hypertension, heart failure, chronic obstructive pulmonary disease, diabetes, and functional status to assess frailty; non-independent functional status was associated with substantially higher postoperative mortality and complications. Such observational associations support individualized risk assessment, not an age-based prohibition on surgery. The C-GALL findings cannot establish the safety of conservative management in medically unfit patients, because that population was excluded from the trial. (journal-of-hepatology.eu)

Surgical treatment

Laparoscopic cholecystectomy—removal of the gallbladder rather than extraction of its stones alone—is the standard operation for symptomatic gallstones in patients fit for surgery. Under general anesthesia, instruments and a camera are introduced through small abdominal incisions; the cystic duct and cystic artery are identified, secured and divided, and the gallbladder is separated from the liver. Compared with open cholecystectomy, laparoscopy generally produces less postoperative pain, shorter hospitalization and faster recovery. Uncomplicated elective procedures can often be performed as day surgery. Open surgery remains an option when laparoscopic dissection cannot proceed safely. (sages.org)

For acute calculous cholecystitis, early surgery during the presenting admission is preferred to routinely waiting for inflammation to subside. The 2020 World Society of Emergency Surgery guidelines specify operation as soon as feasible, within seven days of admission and ten days of symptom onset, when adequate expertise is available. Their evidence synthesis found that early surgery shortened total hospitalization by approximately four days compared with delayed surgery, without a demonstrated increase in bile duct injury or conversion to open surgery. When early operation cannot be undertaken, delayed cholecystectomy beyond six weeks is an alternative. Septic shock or an absolute anesthetic contraindication changes the immediate strategy: resuscitation, antibiotics and gallbladder drainage may precede definitive surgery in patients temporarily unsuitable for an operation. High operative risk alone is not equivalent to being inoperable. (pmc.ncbi.nlm.nih.gov)

Timing also depends on associated disease. Mild gallstone pancreatitis generally warrants cholecystectomy before discharge. In the 2015 PONCHO randomized trial, involving 266 patients at 23 Dutch centers, gallstone-related readmission occurred in 17% after interval surgery versus 5% after same-admission surgery. By contrast, pancreatitis accompanied by peripancreatic fluid collections warrants deferral until the collections resolve or stabilize and acute inflammation has ceased. Endoscopic clearance of a duct stone does not remove the gallbladder source of subsequent stones and therefore does not ordinarily replace cholecystectomy in an otherwise suitable surgical candidate. (pmc.ncbi.nlm.nih.gov)

Operative complications include bleeding, infection, bile leakage and injury to the major bile ducts. The 2020 multisociety safe-cholecystectomy guideline reported major bile duct injury rates of approximately 0.15–0.36% in large studies. A principal preventive measure is the “critical view of safety”: clearing fat and fibrous tissue from the hepatocystic triangle, separating the lower third of the gallbladder from its liver bed, and confirming that only two structures—the cystic duct and artery—enter the gallbladder before either is divided. Uncertain anatomy or suspected injury warrants intraoperative biliary imaging. If severe inflammation, adhesions or bleeding prevents safe identification, options include subtotal cholecystectomy, which leaves part of the gallbladder wall, or conversion to open surgery. Subtotal removal avoids hazardous dissection but carries risks of bile leakage and residual stones; conversion is a safety decision and does not itself guarantee avoidance of duct injury. Suspected major injuries warrant referral to an experienced hepatobiliary team. (sages.org)

Common bile duct stones require duct clearance as well as treatment of the gallbladder. Intraoperative cholangiography or laparoscopic ultrasonography can establish stone location and duct anatomy. A single-stage operation combines cholecystectomy with laparoscopic duct exploration: small distal stones may be retrieved through the cystic duct, whereas larger or proximal stones may require an incision into the common bile duct, termed a choledochotomy. Alternatively, endoscopic retrograde cholangiopancreatography (ERCP) can clear the duct before, during or after cholecystectomy. Stones discovered intraoperatively can therefore be treated immediately or by postoperative ERCP. Comparative evidence supports both single-stage exploration and staged ERCP–cholecystectomy; sequencing depends on stone burden, duct anatomy, equipment and local surgical and endoscopic expertise. (sages.org)

Non-surgical and endoscopic treatment

Endoscopic retrograde cholangiopancreatography (ERCP) treats stones in the common bile duct rather than stones confined to the gallbladder. A flexible endoscope passes through the mouth to the duodenum; a catheter enters the bile duct through the major duodenal papilla, and injected contrast outlines the duct under fluoroscopy. Endoscopic sphincterotomy uses an electrosurgical incision to enlarge the biliary opening, allowing stones to be withdrawn with a balloon or wire basket and restoring bile drainage. Because ERCP carries greater risk than diagnostic imaging, its principal role is therapeutic rather than simply confirming suspected stones. (niddk.nih.gov)

Large or impacted duct stones may require sphincterotomy combined with large-balloon dilation, mechanical crushing, or cholangioscopy-guided laser or electrohydraulic lithotripsy. The latter techniques deliver fragmentation energy directly to stones inside the duct and differ from externally applied shock waves. When immediate clearance is unsuccessful, a temporary biliary stent can maintain drainage, but requires planned removal or exchange. The American Society for Gastrointestinal Endoscopy’s 2019 guideline reported adverse events in approximately 6–15% of ERCP procedures for duct stones, including pancreatitis, bleeding, infection, and perforation. Clearing the duct does not remove stones remaining in the gallbladder; subsequent gallbladder surgery is therefore considered separately. (pmc.ncbi.nlm.nih.gov)

Oral ursodeoxycholic acid (UDCA, or ursodiol) changes bile from a cholesterol-precipitating to a cholesterol-solubilizing medium, permitting gradual dissolution of cholesterol stones. Its use is restricted to selected patients, particularly those with increased surgical risk or who decline surgery. Favorable characteristics include small, noncalcified cholesterol stones and a functioning gallbladder; pigment stones and calcified stones do not respond. U.S. labeling specifies radiolucent stones smaller than 20 mm, although the likelihood of dissolution is substantially greater for stones measuring 5 mm or less. Treatment commonly lasts months to two years. Labeling reports complete dissolution in about 30% of broadly selected patients with noncalcified stones smaller than 20 mm treated for up to two years. (dailymed.nlm.nih.gov)

The labeled UDCA regimen is 8–10 mg/kg/day in divided doses, with ultrasound monitoring at six-month intervals during the first year. Lack of partial dissolution by 12 months substantially reduces the prospect of eventual success. Dissolution does not reliably prevent biliary pain or complications, and recurrence remains substantial because the gallbladder and underlying stone-forming conditions persist. The European Association for the Study of the Liver’s 2016 guideline reported recurrence of 25–64% within five years after bile-acid dissolution and recommended against routine oral litholysis, either alone or combined with shock-wave treatment, for gallbladder stones. (dailymed.nlm.nih.gov)

Contact dissolution delivers a cholesterol-dissolving solvent, notably methyl tert-butyl ether, directly into the gallbladder through a percutaneous transhepatic catheter. Repeated instillation and aspiration provide concentrated solvent–stone contact. A 1998 survey of 21 European hospitals included 803 selected patients: catheter placement succeeded in 761, and stones dissolved in 724 of these patients, although residual sludge remained in 43.5%. Bile leakage led to cholecystectomy in 12 patients. Five-year recurrence was approximately 40% after treatment of solitary stones and 70% after treatment of multiple stones. Despite rapid dissolution, invasive catheter access, leakage risk, residual material, and frequent recurrence have limited the technique to an exceptional rather than routine role. (pubmed.ncbi.nlm.nih.gov)

Extracorporeal shock-wave lithotripsy (ESWL) focuses externally generated pressure waves on gallbladder stones, fragmenting them rather than removing the gallbladder. Successful clearance depends on fragment passage and often adjunctive bile-acid dissolution. Selection favors a small stone burden and preserved gallbladder function. Pigment-rich stones are less suitable: experimental studies found better fragmentation of cholesterol-rich stones, while pigment fragments are not dissolved by UDCA. Fragmentation therefore does not necessarily produce complete clearance. The 2016 EASL guideline reported stone-free outcomes in only about 55% of carefully selected patients, while the 2016 World Society of Emergency Surgery guideline cited recurrence of 30–50% at five years after ESWL. (pubmed.ncbi.nlm.nih.gov)

Prevention and lifestyle

Dietary fat affects gallstone risk through both bile composition and gallbladder emptying; the evidence does not support treating all fats as equivalent. Dietary fat stimulates gallbladder contraction, whereas prolonged fasting reduces opportunities for emptying. Observational studies associate monounsaturated and polyunsaturated fats, including those in nuts, with lower risk, but these associations do not establish a preventive effect of particular foods. The 2016 European Association for the Study of the Liver (EASL) guidelines classified evidence for lifestyle prevention as low quality. Regular meals have a physiological rationale, although an optimal meal frequency has not been established. In a prospective study of 4,730 women, longer overnight fasting was associated with more hospitalizations for gallstone disease over approximately ten years. (easl.eu)

Evidence for dietary fiber likewise comes mainly from observational research rather than prevention trials. In 2004, Chung-Jyi Tsai and colleagues reported results from 69,778 participants in the Nurses’ Health Study: during 16 years, 5,771 women underwent gallbladder removal. Women in the highest fifth of total fiber intake had an adjusted relative risk of 0.87 compared with those in the lowest fifth, equivalent to a 13% lower relative risk. This outcome measured disease leading to surgery, not every newly formed stone, and therefore cannot establish that fiber supplementation prevents stone formation. (pubmed.ncbi.nlm.nih.gov)

Weight maintenance and the rate of weight reduction are distinct determinants of risk. Obesity is associated with cholesterol-rich bile and impaired gallbladder function, but rapid weight loss can also increase hepatic cholesterol secretion into bile and reduce gallbladder emptying. Consequently, severe calorie restriction can temporarily increase risk despite reducing body weight. Repeated weight loss and regain is another associated exposure. The US National Institute of Diabetes and Digestive and Kidney Diseases describes an initial reduction of 5–10% of starting weight over six months as a general weight-management target; it is not a proven threshold below which gallstones cannot occur. (niddk.nih.gov)

Physical activity is associated with lower risk, potentially through effects on bile stasis and lipid metabolism as well as body weight. Paul Banim and colleagues’ 2010 EPIC-Norfolk study followed 25,639 adults aged 40–74. After five years, the most active group had an adjusted hazard ratio of 0.30 relative to the three less-active groups combined. At 14 years, however, the estimate had attenuated to 0.70, with a 95% confidence interval of 0.49–1.01. The association therefore supports a possible protective effect but does not establish a gallstone-specific exercise prescription or a consistent 70% reduction over longer periods. (pubmed.ncbi.nlm.nih.gov)

Coffee and cholesterol-lowering drugs have suggestive but incomplete evidence. Michael Leitzmann and colleagues’ 1999 study of 46,008 men found adjusted relative risks of 0.60 for consistently drinking two to three cups of caffeinated coffee daily and 0.55 for four or more, compared with no regular coffee; decaffeinated coffee showed no inverse association. Other studies have been inconsistent. Statins inhibit hepatic cholesterol synthesis and may reduce biliary cholesterol: Michael Bodmer and colleagues’ 2009 case-control study found an adjusted odds ratio of 0.64 for gallstone disease followed by surgery among current users with at least 20 prescriptions. Neither observational finding establishes an indication to start coffee or statins solely for prevention. EASL also judged alcohol associations inconsistent and did not endorse alcohol as a preventive measure. (pubmed.ncbi.nlm.nih.gov)

Targeted prevention is most relevant when baseline risk is high, especially during very-low-calorie diets or rapid weight loss after bariatric surgery; ursodeoxycholic acid can reduce stone formation in these settings, whereas population-wide drug prophylaxis is not indicated. (niddk.nih.gov) Routine ultrasound screening of symptom-free, average-risk adults is not standard preventive practice: most incidentally detected gallbladder stones do not require treatment, and detection alone does not establish a beneficial intervention. NICE’s diagnostic framework instead directs investigation toward suspected gallstone disease or persistent unexplained abdominal or gastrointestinal symptoms. (ncbi.nlm.nih.gov)

Special populations

During pregnancy, hormonal changes increase biliary cholesterol concentrations and impair gallbladder emptying, favoring cholesterol supersaturation, biliary sludge, and stones. A prospective study published in 2005 by Cynthia W. Ko and colleagues followed 3,254 women without stones on their initial ultrasound: sludge or stones had appeared on at least one examination in 5.1% by the second trimester, 7.9% by the third trimester, and 10.2% by four to six weeks postpartum. These were combined sludge-and-stone figures, not the incidence of established gallstones alone; regression was common. (sages.org) Pregnancy does not preclude necessary gallbladder surgery. The 2024 Society of American Gastrointestinal and Endoscopic Surgeons guidelines conditionally favor laparoscopic cholecystectomy over nonoperative treatment for biliary disease during pregnancy, particularly acute cholecystitis, although the evidence is predominantly observational. For uncomplicated biliary colic in the third trimester, either operative or nonoperative management may be appropriate, depending on disease severity, recurrence, and gestational age. Medically necessary surgery should not be delayed solely because of trimester; obstetric involvement and appropriate fetal monitoring are part of perioperative care. (pmc.ncbi.nlm.nih.gov)

In children and adolescents, associated conditions include hemolytic anemia, sickle cell disease, hereditary spherocytosis, thalassemia, intestinal disease or resection, prolonged parenteral nutrition, and obesity. Chronic erythrocyte destruction increases bilirubin delivery to bile and favors calcium bilirubinate pigment stones, whereas obesity is associated with cholesterol-stone disease. (link.springer.com) Corinna Koebnick and colleagues’ 2012 study of 510,816 adolescents aged 10–19 identified 766 diagnosed cases. Compared with normal-weight or underweight participants, adjusted odds of gallstones in those with extreme obesity were 3.10 times higher in boys and 7.71 times higher in girls. These estimates describe diagnosed disease in a cross-sectional population, rather than stones detected through universal screening. (pmc.ncbi.nlm.nih.gov) Pediatric assessment also distinguishes persistent stones from ceftriaxone-associated biliary precipitates, which can resolve after the drug is discontinued. In a 2022 prospective series of 42 children, symptomatic gallbladder stones were treated principally by laparoscopic cholecystectomy, while drug-associated deposits were observed and resolved in the two affected children. (link.springer.com)

After bariatric surgery, rapid weight loss increases the lithogenicity of bile, while reduced intake and impaired gallbladder emptying contribute to stasis. The 2021 Enhanced Recovery After Surgery Society recommendations support considering ursodeoxycholic acid for six months after surgery in patients without pre-existing gallstones; symptomatic stones may instead warrant cholecystectomy before or during the bariatric procedure. (ncbi.nlm.nih.gov) Evidence differs between prevention of ultrasound-detected stones and prevention of symptomatic disease. In Sylke Haal and colleagues’ 2021 UPGRADE randomized controlled trial, 900 mg daily for six months produced symptomatic disease within two years in 6.5% of treated participants versus 9.7% receiving placebo; the overall difference was not statistically significant. Benefit was demonstrated in participants without baseline stones undergoing Roux-en-Y gastric bypass, but not in those with pre-existing asymptomatic stones. The sleeve-gastrectomy subgroup was too small for firm conclusions. (pubmed.ncbi.nlm.nih.gov)

With total parenteral nutrition, absence of normal enteral stimulation reduces meal-related cholecystokinin release and gallbladder contraction. Sludge can therefore accumulate even without the metabolic changes accompanying weight loss. A 1991 study of infants found sludge in 23% after one month of continuous parenteral nutrition; sludge disappeared in children receiving full oral feeding, alongside restoration of postprandial cholecystokinin secretion. (pubmed.ncbi.nlm.nih.gov) Earlier work by Bernard Messing and colleagues, published in 1983, followed 23 selected adults and likewise documented increasing sludge with prolonged intravenous feeding and disappearance after oral refeeding. These observations make restoration of enteral stimulation, where feasible, relevant to management; sludge is not necessarily an irreversible stone burden. (pubmed.ncbi.nlm.nih.gov)

Chronic hemolysis changes both stone composition and perioperative planning. In sickle cell disease, biliary symptoms can coexist with other causes of abdominal pain and jaundice, requiring assessment rather than attribution to stones alone. The US National Heart, Lung, and Blood Institute’s 2014 expert-panel report recommends watchful waiting for asymptomatic gallstones in children and adults with sickle cell disease, laparoscopic cholecystectomy for gallstone-specific symptoms, and hematology consultation concerning possible preoperative transfusion. Acute cholecystitis requires antibiotics and automatic indication for prophylactic gallbladder removal under that guidance. (childrensnational.org)

History of understanding and treatment

Early descriptions of gallstones emerged from the examination of diseased organs rather than from a unified theory of biliary disease. Antonio Benivieni’s posthumously published De abditis nonnullis ac mirandis morborum et sanationum causis (1507) included observations of gallstones among its accounts of concealed causes of illness. More detailed anatomical investigation followed in Francis Glisson’s Anatomia Hepatis (1654). Glisson injected the liver’s vascular and biliary networks and removed surrounding tissue to examine their arrangement, documenting the intrahepatic ducts, gallbladder, and common bile duct extending to the duodenum. Although parts of his explanation of liver function were incorrect, he recognized that stones lodged in bile ducts could cause severe pain. (treccani.it)

Nineteenth-century operative treatment initially concentrated on draining infected gallbladders or extracting stones while leaving the organ in place. John Stough Bobbs performed a stone-removing cholecystotomy in Indianapolis in 1867. Carl Langenbuch subsequently developed cholecystectomy, reasoning that removing the gallbladder addressed the site of stone formation rather than merely its contents. After experimental work and cadaver dissections, he performed the first successful operation at Berlin’s Lazarus Hospital on July 15, 1882. His patient recovered, and the procedure was reported that November. Despite initial opposition, gallbladder removal became established practice; open cholecystectomy remained the principal definitive operation for approximately a century. (pubmed.ncbi.nlm.nih.gov)

Twentieth-century chemical research made stone formation experimentally tractable, rather than first discovering that stones contained cholesterol. A pivotal study by William H. Admirand and Donald M. Small, published in 1968, compared 66 gallbladder-bile samples from patients with cholesterol stones with 25 normal samples. Plotting cholesterol, bile salts, and lecithin on triangular coordinates connected their relative proportions with cholesterol solubility and crystal formation. This physicochemical approach supported attempts to reverse precipitation by altering bile composition. In 1972, Rudy G. Danzinger, Alan F. Hofmann, Leslie J. Schoenfield, and Johnson L. Thistle reported oral chenodeoxycholic-acid treatment in seven women: stones disappeared in one and became smaller in three others, demonstrating that some cholesterol stones could dissolve without surgery. (jci.org)

Imaging and endoscopy changed how stones were detected and treated. By 1974, clinical studies were directly comparing ultrasonic examination with radiographic cholecystography; ultrasound subsequently became the first-line examination in gallstone guidelines. William S. McCune, Paul E. Shorb, and Herbert Moscovitz reported endoscopic cannulation of the ampulla of Vater in 1968, an early foundation of endoscopic retrograde cholangiopancreatography (ERCP). In 1974, Keiichi Kawai and colleagues published endoscopic sphincterotomy of the ampulla. Cutting the sphincter provided an endoscopic route for treating duct stones, extending endoscopy beyond visualization and contrast imaging. (pubmed.ncbi.nlm.nih.gov)

The transition from open to laparoscopic surgery began with Erich Mühe’s first laparoscopic cholecystectomy in Böblingen, Germany, on September 12, 1985. Mühe used a specially designed “galloscope,” clip applicators, and scissors to divide the cystic duct and artery and remove the gallbladder through limited access. Philippe Mouret performed a video-assisted laparoscopic cholecystectomy in Lyon on March 17, 1987. Further development and dissemination transformed surgical practice during the following decade, replacing the large-incision operation with a minimally invasive approach for most routine cases. (pmc.ncbi.nlm.nih.gov)

International guidelines subsequently formalized treatment selection through evidence-based medicine and structured assessment of disease severity. The Tokyo Guidelines, first published in 2007 and revised in 2013 and 2018, established diagnostic criteria, severity grades, and management pathways for acute cholecystitis and cholangitis. Their development reflected a change from initially treating acute inflammation as a contraindication to laparoscopy toward accepting laparoscopic treatment by appropriately experienced surgeons. The European Association for the Study of the Liver’s 2016 gallstone guidelines distinguished observation of uncomplicated asymptomatic stones from surgery for symptomatic disease, favored laparoscopic cholecystectomy, and discouraged routine dissolution treatment because successful clearance did not eliminate the substantial risk of recurrence. (doi.org)

Current research and unresolved questions

GLP-1 receptor agonists, used for type 2 diabetes and obesity, have brought renewed attention to treatment-associated gallstone risk. A 2022 meta-analysis of 76 randomized clinical trials, involving 103,371 participants, found increased gallbladder or biliary disease with these drugs: relative risk 1.37, with a 95% confidence interval of 1.23–1.52. The relative risk specifically for gallstones was 1.27; for the broader biliary outcome, it reached 2.29 in weight-loss trials. Associations were stronger with higher doses and longer treatment. Randomization supports an effect of treatment, but does not distinguish direct pharmacological effects from effects mediated by weight loss. A 2018 placebo-controlled liraglutide study found delayed time to maximum gallbladder contraction without reduced maximum emptying, illustrating why a simple “reduced contraction” explanation is insufficient. The unresolved causal question concerns the relative contributions of altered motility, weight loss, and other drug-mediated changes. (pubmed.ncbi.nlm.nih.gov)

Research on genetic susceptibility increasingly connects risk variants to particular components of bile rather than treating gallstones as a single inherited phenotype. A 2018 genome-wide association analysis included 27,174 cases and 736,838 controls. Established associations included ABCG5/ABCG8, encoding transporters that secrete cholesterol into bile, and ABCB4, responsible for biliary phospholipid secretion. The analysis also identified SLC10A2 variants affecting the intestinal bile-acid transporter: Pro290Ser and Val98Ile were associated with odds ratios of 1.36 and 1.15, respectively. Both have experimentally reduced transport activity, linking susceptibility to impaired bile-acid recycling. Associations involving CYP7A1, which participates in bile-acid synthesis, provide another connection between inherited variation and cholesterol solubility. These findings identify biological pathways, but do not by themselves establish which carriers will develop symptoms or benefit from preventive intervention. (nature.com)

Studies of the gut microbiome investigate whether intestinal organisms help produce lithogenic bile rather than merely changing after disease develops. A 2022 experimental study implicated microbiota enriched in Desulfovibrionales in cholesterol-stone formation. Proposed mechanisms included increased microbial conversion of primary to secondary bile acids and production of hydrogen sulfide, which altered hepatic farnesoid X receptor (FXR) signaling and suppressed CYP7A1. The resulting changes increased bile-acid hydrophobicity, intestinal cholesterol absorption, and biliary cholesterol secretion. These experiments provide mechanistic evidence in experimental systems; they do not establish that the same microbial changes initiate human disease or that modifying those organisms prevents clinical events. (pmc.ncbi.nlm.nih.gov)

Bile-acid signaling is consequently a potential therapeutic target, but effects differ between tissues and receptors. A 2022 mouse study investigated Lactobacillus strains and linked their effects on cholesterol stones to FXR-mediated bile-acid metabolism. Research on TGR5, a cell-surface bile-acid receptor, highlights a competing concern: receptor activation can produce desirable metabolic effects while increasing gallbladder filling. In a 2011 study, lithocholic acid and the synthetic agonist INT-777 increased gallbladder volume in wild-type mice but not mice lacking TGR5; tissue experiments linked this response to increased cyclic AMP and smooth-muscle relaxation. Such findings make tissue selectivity and gallbladder effects important questions in developing receptor-directed therapies, rather than demonstrating an established human stone-prevention treatment. (pubmed.ncbi.nlm.nih.gov)

Clinical uncertainties concern both intervention thresholds and individual prediction. A 2005 study associated small stones and preserved gallbladder motility with pancreatitis, but this does not establish that prophylactic surgery improves outcomes in otherwise asymptomatic people. A longitudinal study of asymptomatic stones developed a prediction model incorporating factors including age, sex, stone number, stone size, and hemolytic anemia; its C-statistic of 0.70 indicates incomplete discrimination between those who will and will not develop symptoms. For uncomplicated symptomatic disease, the 2023 C-GALL trial randomized 434 adults and found no difference in overall bodily pain over 18 months between conservative and surgical strategies, although gallbladder-specific outcomes favored surgery. By that point, 25% and 67% of the respective groups had undergone surgery. Patients medically unfit for surgery were excluded, leaving the balance between recurrent biliary events and operative risk in patients with substantial comorbidity less directly addressed by this trial. (pubmed.ncbi.nlm.nih.gov)

References

1. Definition & Facts for Gallstones - NIDDKniddk.nih.gov
2. Definition of gallstone - NCI Dictionary of Cancer Terms - NCIcancer.gov
3. Choledocholithiasis and Cholangitis - Merck Manual Professional Editionmerckmanuals.com
4. Hepatolithiasis: Epidemiology, presentation, classification and management of a complex diseasepmc.ncbi.nlm.nih.gov
5. Anatomy, Abdomen and Pelvis: Gallbladder - StatPearlsncbi.nlm.nih.gov
6. Physiology, Gallbladder - StatPearlsncbi.nlm.nih.gov
7. Gallstones (Cholelithiasis) - StatPearlsncbi.nlm.nih.gov
8. Gallstone size and risk of pancreatitispubmed.ncbi.nlm.nih.gov
9. Treatment for Gallstones - NIDDKniddk.nih.gov
10. Physiological and molecular biochemical mechanisms of bile formationpmc.ncbi.nlm.nih.gov
11. Aqueous bile salt-lecithin-cholesterol systems: equilibrium aspects.pubmed.ncbi.nlm.nih.gov
12. Critical tables for calculating the cholesterol saturation of native bilepubmed.ncbi.nlm.nih.gov
13. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man.jci.org
14. Cholesterol precipitation from cholesterol-supersaturated bile models.pubmed.ncbi.nlm.nih.gov
15. Classification of gallstones using Fourier-transform infrared spectroscopy and photographypmc.ncbi.nlm.nih.gov
16. The Systematic Classification of Gallbladder Stonespmc.ncbi.nlm.nih.gov
17. Robbins and Cotran Pathologic Basis of Diseaseelsevier-elibrary.com
18. Pathogenesis of gallstonespubmed.ncbi.nlm.nih.gov
19. Gallbladder sludge: spontaneous course and incidence of complications in patients without stonespubmed.ncbi.nlm.nih.gov
20. Fixed-point and stratified analysis of the fine structure and composition of five gallstones with Fourier transform infrared (FT-IR) specular reflection spectroscopypubmed.ncbi.nlm.nih.gov
21. Chemical Characterization of Gallstones: An Approach to Explore the Aetiopathogenesis of Gallstone Disease in Sri Lankapmc.ncbi.nlm.nih.gov
22. Actigallaccessdata.fda.gov
23. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterolpubmed.ncbi.nlm.nih.gov
24. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone diseasepubmed.ncbi.nlm.nih.gov
25. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstonespubmed.ncbi.nlm.nih.gov
26. Human gallbladder mucin binds biliary lipids and promotes cholesterol crystal nucleation in model bilepubmed.ncbi.nlm.nih.gov
27. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bilepubmed.ncbi.nlm.nih.gov
28. Direct contractile response of isolated gallbladder smooth muscle cells to cholecystokinin in patients with gallstonespubmed.ncbi.nlm.nih.gov
29. Excess membrane cholesterol alters human gallbladder muscle contractility and membrane fluiditypubmed.ncbi.nlm.nih.gov
30. CCK receptor dysfunction in muscle membranes from human gallbladders with cholesterol stonespubmed.ncbi.nlm.nih.gov
31. Cholesterol gallstone pathogenesis: a study of potential nucleating agents for cholesterol crystal formation in bilepubmed.ncbi.nlm.nih.gov
32. Cholesterol gallstone dissolution in bile. Dissolution kinetics of crystalline cholesterol monohydrate by conjugated chenodeoxycholate-lecithin and conjugated ursodeoxycholate-lecithin mixtures: dissimilar phase equilibria and dissolution mechanismspubmed.ncbi.nlm.nih.gov
33. Partial replacement of bile salts causes marked changes of cholesterol crystallization in supersaturated model bile systemspmc.ncbi.nlm.nih.gov
34. New pathophysiological concepts underlying pathogenesis of pigment gallstonespmc.ncbi.nlm.nih.gov
35. The etiology of pigment gallstonespubmed.ncbi.nlm.nih.gov
36. On the chemistry of 'black' pigment stones from the gallbladder.pubmed.ncbi.nlm.nih.gov
37. Mucin glycoprotein content of human pigment gallstonespubmed.ncbi.nlm.nih.gov
38. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemiapubmed.ncbi.nlm.nih.gov
39. Primary bile duct stones and bacterial activity.pubmed.ncbi.nlm.nih.gov
40. Pigment gallstone pathogenesis: slime production by biliary bacteria is more important than beta-glucuronidase productionpubmed.ncbi.nlm.nih.gov
41. Bile and stone analysis in two infants with brown pigment gallstones and infected bile.pubmed.ncbi.nlm.nih.gov
42. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cyclepubmed.ncbi.nlm.nih.gov
43. Effects of pregnancy and contraceptive steroids on gallbladder functionpubmed.ncbi.nlm.nih.gov
44. The effect of a progestin on gallbladder function in young womenpubmed.ncbi.nlm.nih.gov
45. Influence of age on secretion of cholesterol and synthesis of bile acids by the liverpubmed.ncbi.nlm.nih.gov
46. Effect of estrogen therapy on gallbladder diseasepubmed.ncbi.nlm.nih.gov
47. Dieting & Gallstones - NIDDKniddk.nih.gov
48. Hepatic insulin resistance directly promotes formation of cholesterol gallstonespubmed.ncbi.nlm.nih.gov
49. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort studypubmed.ncbi.nlm.nih.gov
50. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairspubmed.ncbi.nlm.nih.gov
51. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone diseasepubmed.ncbi.nlm.nih.gov
52. Prevalence of gallbladder disease in American Indian populations: findings from the Strong Heart Studypubmed.ncbi.nlm.nih.gov
53. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancerpmc.ncbi.nlm.nih.gov
54. Etiology of cholelithiasis].pubmed.ncbi.nlm.nih.gov
55. Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intakepubmed.ncbi.nlm.nih.gov
56. Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project)pmc.ncbi.nlm.nih.gov
57. Global burden of gallbladder and biliary diseases (1990–2021) with healthcare workforce analysis and projections to 2035d-nb.info
58. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstonescdn.ncpodcast.net
59. Key priorities for implementation: Gallstone disease—diagnosis and managementnice.org.uk
60. Gallstonesnhs.uk
61. Symptoms & Causes of Gallstonesniddk.nih.gov
62. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)pubmed.ncbi.nlm.nih.gov
63. ASGE: The role of endoscopy in the management of choledocholithiasisasge.org
64. Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groupspmc.ncbi.nlm.nih.gov
65. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelinespmc.ncbi.nlm.nih.gov
66. Introduction and Background: National Commission on Digestive Diseases Research Planniddk.nih.gov
67. Acute pancreatitis: MedlinePlus Medical Encyclopediamedlineplus.gov
68. Gallstones: Learn More – Complications of gallstonesncbi.nlm.nih.gov
69. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infectionspmc.ncbi.nlm.nih.gov
70. Gallstone ileuspubmed.ncbi.nlm.nih.gov
71. Risk Factors for Gallbladder Cancercancer.org
72. Gallstone size and the risk of gallbladder cancerpubmed.ncbi.nlm.nih.gov
73. ACR Appropriateness Criteria: Right Upper Quadrant Pain—Evidence Tableacsearch.acr.org
74. A prospective, blinded comparison of laparoscopic ultrasound with transabdominal ultrasound for the detection of gallbladder pathology in morbidly obese patientspubmed.ncbi.nlm.nih.gov
75. ACR Appropriateness Criteria: Right Upper Quadrant Painacsearch.acr.org
76. ACR Appropriateness Criteria: Right Upper Quadrant Pain, Revised 2022acsearch.acr.org
77. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasisasge.org
78. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasisasge.org
79. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstoneseasl.eu
80. American College of Gastroenterology Guidelines: Management of Acute Pancreatitispmc.ncbi.nlm.nih.gov
81. NICE Guideline Template: Gallstone diseasenice.org.uk
82. Evidence-based clinical practice guidelines for cholelithiasis 2021pmc.ncbi.nlm.nih.gov
83. Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGEpubmed.ncbi.nlm.nih.gov
84. Gallstone disease: diagnosis and managementnice.org.uk
85. Role of mFI-5 in predicting geriatric outcomes in laparoscopic cholecystectomypubmed.ncbi.nlm.nih.gov
86. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitispmc.ncbi.nlm.nih.gov
87. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitispmc.ncbi.nlm.nih.gov
88. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasispmc.ncbi.nlm.nih.gov
89. 2019 WSES guidelines for the management of severe acute pancreatitispmc.ncbi.nlm.nih.gov
90. Endoscopic Retrograde Cholangiopancreatography (ERCP) - NIDDKniddk.nih.gov
91. DailyMed - URSODIOL capsuledailymed.nlm.nih.gov
92. DailyMed - URSODIOL capsuledailymed.nlm.nih.gov
93. Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey.pubmed.ncbi.nlm.nih.gov
94. Gallstone fragmentation during biliary lithotripsy: effect of stone composition and structure.pubmed.ncbi.nlm.nih.gov
95. 2016 WSES guidelines on acute calculous cholecystitispmc.ncbi.nlm.nih.gov
96. A prospective study of hospitalization with gallstone disease among women: role of dietary factors, fasting period, and dietingpmc.ncbi.nlm.nih.gov
97. Long-term intake of dietary fiber and decreased risk of cholecystectomy in womenpubmed.ncbi.nlm.nih.gov
98. Physical activity reduces the risk of symptomatic gallstones: a prospective cohort studypubmed.ncbi.nlm.nih.gov
99. A prospective study of coffee consumption and the risk of symptomatic gallstone disease in menpubmed.ncbi.nlm.nih.gov
100. Statin use and risk of gallstone disease followed by cholecystectomypubmed.ncbi.nlm.nih.gov
101. Evidence Review and Recommendations - Gallstone Diseasencbi.nlm.nih.gov
102. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancypubmed.ncbi.nlm.nih.gov
103. SAGES guidelines for the use of laparoscopy during pregnancypmc.ncbi.nlm.nih.gov
104. Pediatric biliary calculus disease: clinical spectrum, predisposing factors, and management outcome revisitedlink.springer.com
105. Pediatric obesity and gallstone disease: results from a cross-sectional study of over 510,000 youthpmc.ncbi.nlm.nih.gov
106. Medical Management of the Post Operative Bariatric Surgery Patientncbi.nlm.nih.gov
107. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trialpubmed.ncbi.nlm.nih.gov
108. The effect of artificial feeding on cholestasis, gallbladder sludge and lithiasis in infants: correlation with plasma cholecystokinin levelspubmed.ncbi.nlm.nih.gov
109. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis?pubmed.ncbi.nlm.nih.gov
110. BENIVIENI, Antoniotreccani.it
111. Liver anatomy by Francis Glissonpmc.ncbi.nlm.nih.gov
112. Carl Langenbuch and the Lazarus Hospital: events and circumstances surrounding the first cholecystectomy.pubmed.ncbi.nlm.nih.gov
113. Twenty Years of Laparoscopic Cholecystectomy: Philippe Mouret—March 17, 1987pmc.ncbi.nlm.nih.gov
114. The physicochemical basis of cholesterol gallstone formation in manjci.org
115. Dissolution of cholesterol gallstones by chenodeoxycholic acidpubmed.ncbi.nlm.nih.gov
116. Ultrasonic and radiographic cholecystography. A comparisonpubmed.ncbi.nlm.nih.gov
117. Endoscopic cannulation of the ampulla of Vater: a preliminary report. By William S. McCune, Paul E. Shorb, and Herbert Moscovitz, 1968pubmed.ncbi.nlm.nih.gov
118. Endoscopic sphincterotomy of the ampulla of Vaterpubmed.ncbi.nlm.nih.gov
119. The First Laparoscopic Cholecystectomypmc.ncbi.nlm.nih.gov
120. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trialspubmed.ncbi.nlm.nih.gov
121. Genome-wide association meta-analysis yields 20 loci associated with gallstone diseasenature.com
122. Genome-wide association meta-analysis yields 20 loci associated with gallstone diseasepmc.ncbi.nlm.nih.gov
123. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretionpmc.ncbi.nlm.nih.gov
124. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strainspubmed.ncbi.nlm.nih.gov
125. The G Protein-Coupled Bile Acid Receptor, TGR5, Stimulates Gallbladder Fillingpmc.ncbi.nlm.nih.gov
126. Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitispubmed.ncbi.nlm.nih.gov
127. Scientific summary—Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCTncbi.nlm.nih.gov